BioCardia (BCDA) Projected to Post Earnings on Wednesday

Posted by ABMN Staff on Mar 24th, 2025

BioCardia (NASDAQ:BCDA – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 26th. Analysts expect BioCardia to post earnings of ($0.87) per share and revenue of $0.02 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

BioCardia Price Performance

Shares of BCDA opened at $2.66 on Monday. BioCardia has a 1-year low of $1.63 and a 1-year high of $6.41. The company has a market capitalization of $12.19 million, a P/E ratio of -0.64 and a beta of 1.28. The firm’s 50 day simple moving average is $2.42 and its 200 day simple moving average is $2.41.

Insider Transactions at BioCardia

In other BioCardia news, Director Simon H. Stertzer purchased 22,753 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was bought at an average price of $2.30 per share, with a total value of $52,331.90. Following the completion of the purchase, the director now directly owns 40,602 shares of the company’s stock, valued at $93,384.60. The trade was a 127.47 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have acquired 25,353 shares of company stock worth $58,525. 20.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BCDA has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research report on Wednesday, December 18th. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th.

View Our Latest Analysis on BCDA

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.